中医药配合分子靶向药物治疗非小细胞肺癌的临床研究

Clinical research on treating NSCLC in TCM plus molecular targeted medicine

目的:探讨益气养阴化痰解毒中药配合分子靶向药物治疗非小细胞肺癌的临床效果。方法:60例非小细胞肺癌患者随机分为两组,观察组采用中医药联合吉非替尼治疗,对照组单用吉非替尼,观察两组治疗效果,临床症状及不良反应。结果:观察组患者病情控制率显著、临床症状改善情况显著优于对照组(P<0.01);观察组不良反应发生率较对照组低(P<0.05)。结论:益气养阴化痰解毒中药配合靶向药物治疗非小细胞肺癌效果较好,不良反应率发生低。

Objective： To explore the clinical effect of the TCM plus molecular targeted medicine in treating non-small cell lung cancer （NSCLC）. Methods： 60 patients were randomly divided into two groups, the observation group was treated in TCM plus gefitinib, the control group was given gefitinib alone, the effect, the clinical symptoms and adverse reactions of both groups were observed. Results： The patient＇s condition control rate of the observation group was significantly, clinical improvement of symptoms was significantly better than the control group （P〈0.01）; the incidence of adverse events was lower than that of the control group （P〈0.05）. Conclusion： The effects of TCM plus molecular targeted medicine were good, adverse reaction rates low.